Here’s Why Moderna Just Sank $10 a Share

Test tube of glass overflows new liquid solution potassium blue conducts an analysis reaction takes various versions reagents using chemical pharmaceutics cancer manufacturing

Just this morning, Moderna (MRNA) was downgraded by JP Morgan on valuation concerns.

In fact, analyst Cory Kasimov said that while he is bullish on the stock, MRNA can no longer support the stock’s valuation.

On that news, MRNA fell $10.  However, the pullback may not last long thanks to strong COVID-19 study results.  Remember, not only ago, MRNA announced its vaccine was found to induce immune responses in every volunteer in a Phase 1 study.

“These early results, published in the New ...

Register Now

The Daily Chart Newsletter is available only to members of this site. Register now for FREE. No cost, no obligation, join today.

Already a member? Login below, or click here to register now for free.